Plain-English translation of NCT05667506 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether CNCT19, a new type of cell-based treatment, can help children and teenagers whose acute lymphoblastic leukemia (a blood cancer) has returned or is no longer responding to standard treatments. The medication works by training immune cells from the patient's own body to recognize and fight leukemia cells. Researchers want to find out if this treatment is safe and how well it works in children ages 3 to 18.
When children's leukemia comes back or stops responding to chemotherapy, treatment options become limited and outcomes can be poor. This trial exists to test whether this new cell-based treatment can offer hope and better results for young patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will first receive conditioning chemotherapy (fludarabine and cyclophosphamide) to prepare your body for the new treatment. Then you will receive an infusion of CNCT19—the investigational cell-based medication. After the infusion, you will be closely monitored for safety and how well the treatment is working through regular visits, blood tests, and other assessments. All participants are followed for up to 2 years after receiving the treatment to track long-term outcomes and any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China